PHG · PHG Q2 FY2026 earnings call record财报电话会记录

“We grew comparable sales by 4%, driven by growth across all segments.”

“Against this backdrop, we reiterate our full-year comparable sales growth outlook range of 3%-4.5%, and our underlying adjusted EBITDA margin outlook also remains unchanged.”

“In IGT, North America continued to deliver an exceptionally strong win rate, supported by large customer orders.”

“Together, these examples underscore that customers increasingly recognize the value of patient monitoring as an enterprise platform integrated with software and clinical informatics.”

“Our platform-based portfolio, differentiated innovation, and strong customer engagement positions us very well to capture that demand in North America.”

“Adjusted EBITDA margin increased by 40 basis points year-over-year to 13.9%, including the impact of the tariff refund, which I will discuss later.”

“In Q2, Personal Health adjusted EBITDA margin expanded by approximately 780 basis points to 23%, including the impact of the tariff refund.”

“Finally, sales in segment other increased by EUR 62 million to EUR 182 million, mainly due to higher royalty income and activities related to a divestment.”

“Given the year-to-date performance, we anticipate a full-year impact of approximately 180 basis points, compared with our previous outlook of approximately 200 basis points.”

“We are on track with 10 basis points of margin expansion for the first half, and we are reiterating our full year margin outlook for the year between 20 and 70 basis points.”

“Also, as you rightly say, at CMD, we have been very clear about our EBITDA margin bridge, where we put in roughly 200 basis points for FX and macro uncertainty.”

“First of all, there's higher volumes, as a result, I think you know this, Veronika, that gives us a ton of operating leverage.”